In a recent precedential opinion, the Federal Circuit rejected arguments by Amgen that a single step purification process used by Sandoz...
BiosimilarsIP.com Legal provides analysis of legal decisions from federal courts and from the PTAB related to biologics and biosimilars.
-
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
-
By Nicole DeAbrantes Comments are off
On May 20, 2019, the PTAB denied a request for rehearing in Apotex Inc. v. Amgen Inc., Case IPR2016-01542 (Paper 67), but modified its...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Nicole DeAbrantes Comments are off
Recently, in Adello Biologics LLC v. Amgen Inc., Case PGR2019-00001 (Paper No. 13) (PTAB Apr. 19, 2019), the PTAB instituted...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Seth Cockrum Comments are off
On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
Posted in:
The PTAB Denies Institution of Two IPRs Involving a Patent Directed to the Treatment of Hemophilia B
By Seth Cockrum Comments are off
The PTAB recently denied institution of two IPRs filed by CSL Behring LLC, CSL Behring GMBH, and CSL Behring Recombinant Facility AG...
Tagged with: Aprolix®, Bioverativ Therapetutics, BLA, CSL Behring, Idelvion®, IPR, PTAB
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
Posted in:
FDA Issues Guidance Documents on the “Deemed to be a License” Transition Provision of the BPCIA
By Seth Cockrum Comments are off
The Biologics Price Competition and Innovation Act (“BPCIA”) requires applications to market a biological product be submitted for...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Caitlin M. Wilmot Comments are off
Last month, the FDA released four new guidance documents providing insight on the FDA’s interpretation of provisions of the Biologics...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus